These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 12223434)

  • 1. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.
    Ariyoshi N; Miyamoto M; Umetsu Y; Kunitoh H; Dosaka-Akita H; Sawamura Y; Yokota J; Nemoto N; Sato K; Kamataki T
    Cancer Epidemiol Biomarkers Prev; 2002 Sep; 11(9):890-4. PubMed ID: 12223434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.
    Fujieda M; Yamazaki H; Saito T; Kiyotani K; Gyamfi MA; Sakurai M; Dosaka-Akita H; Sawamura Y; Yokota J; Kunitoh H; Kamataki T
    Carcinogenesis; 2004 Dec; 25(12):2451-8. PubMed ID: 15308589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
    Wang H; Tan W; Hao B; Miao X; Zhou G; He F; Lin D
    Cancer Res; 2003 Nov; 63(22):8057-61. PubMed ID: 14633739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population.
    Tan W; Chen GF; Xing DY; Song CY; Kadlubar FF; Lin DX
    Int J Cancer; 2001 Mar; 95(2):96-101. PubMed ID: 11241319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk.
    Kamataki T; Fujieda M; Kiyotani K; Iwano S; Kunitoh H
    Biochem Biophys Res Commun; 2005 Dec; 338(1):306-10. PubMed ID: 16176798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism in cytochrome P450 2A6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome.
    Ruwali M; Pant MC; Shah PP; Mishra BN; Parmar D
    Mutat Res; 2009 Oct; 669(1-2):36-41. PubMed ID: 19406142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between CYP2A6 genetic polymorphisms and lung cancer: a meta-analysis of case-control studies.
    Liu T; Xie CB; Ma WJ; Chen WQ
    Environ Mol Mutagen; 2013 Mar; 54(2):133-40. PubMed ID: 23203414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.
    Kamataki T; Fujita K; Nakayama K; Yamazaki Y; Miyamoto M; Ariyoshi N
    Drug Metab Rev; 2002 Aug; 34(3):667-76. PubMed ID: 12214673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population.
    Loriot MA; Rebuissou S; Oscarson M; Cenée S; Miyamoto M; Ariyoshi N; Kamataki T; Hémon D; Beaune P; Stücker I
    Pharmacogenetics; 2001 Feb; 11(1):39-44. PubMed ID: 11207029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2A6 gene deletion reduces susceptibility to lung cancer.
    Miyamoto M; Umetsu Y; Dosaka-Akita H; Sawamura Y; Yokota J; Kunitoh H; Nemoto N; Sato K; Ariyoshi N; Kamataki T
    Biochem Biophys Res Commun; 1999 Aug; 261(3):658-60. PubMed ID: 10441482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms.
    Minematsu N; Nakamura H; Furuuchi M; Nakajima T; Takahashi S; Tateno H; Ishizaka A
    Eur Respir J; 2006 Feb; 27(2):289-92. PubMed ID: 16452582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers.
    O'Loughlin J; Paradis G; Kim W; DiFranza J; Meshefedjian G; McMillan-Davey E; Wong S; Hanley J; Tyndale RF
    Tob Control; 2004 Dec; 13(4):422-8. PubMed ID: 15564629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An association of CYP2A6 genotype and smoking topography.
    Strasser AA; Malaiyandi V; Hoffmann E; Tyndale RF; Lerman C
    Nicotine Tob Res; 2007 Apr; 9(4):511-8. PubMed ID: 17454707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [How I was enticed into molecular toxicology].
    Kamataki T
    Yakugaku Zasshi; 2006 Dec; 126(12):1309-18. PubMed ID: 17139156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Researches on the polymorphism of cytochrome P450 2A6].
    Tong Z; ZhuGe J; Yu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Oct; 19(5):424-7. PubMed ID: 12362322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the Singapore Chinese Health Study.
    Yuan JM; Nelson HH; Carmella SG; Wang R; Kuriger-Laber J; Jin A; Adams-Haduch J; Hecht SS; Koh WP; Murphy SE
    Carcinogenesis; 2017 Apr; 38(4):411-418. PubMed ID: 28182203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults.
    Ando M; Hamajima N; Ariyoshi N; Kamataki T; Matsuo K; Ohno Y
    J Epidemiol; 2003 May; 13(3):176-81. PubMed ID: 12749606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population.
    Islam MS; Ahmed MU; Sayeed MS; Maruf AA; Mostofa AG; Hussain SM; Kabir Y; Daly AK; Hasnat A
    Clin Chim Acta; 2013 Feb; 416():11-9. PubMed ID: 23178447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis.
    Liu YL; Xu Y; Li F; Chen H; Guo SL
    Tumour Biol; 2013 Oct; 34(5):2651-7. PubMed ID: 23649654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of the rate of nicotine metabolism and effects on smoking behavior.
    Johnstone E; Benowitz N; Cargill A; Jacob R; Hinks L; Day I; Murphy M; Walton R
    Clin Pharmacol Ther; 2006 Oct; 80(4):319-30. PubMed ID: 17015050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.